Caliper Life Sciences, a Perkin-Elmer Company, has launched the Vectra 2 with AQUA technology, an integrated solution for quantification of protein biomarkers in tissue, at the Molecular Targets & Cancer Therapeutics meeting here this week. Caliper and HistoRx collaborated on this new immunofluorescent imaging and analysis solution that will deliver objective, quantitative, and reproducible results: an improvement on traditional immunohistochemistry. The new product enables users to leverage the combined imaging and analysis power of Caliper’s Vectra 2, an automated multiplexed and multispectral tissue imaging platform, and AQUA technology, HistoRx’s proprietary image analysis system, to provide an integrated solution to advance the identification and validation of new drug targets and improve assessment of drug response.
“The Vectra 2 with AQUA technology represents a significant move forward for those interested in digital pathology with both brightfield and fluorescent capabilities,” said Mark Gustavson, Ph.D., Director of Operations at HistoRx. “By matching AQUA technology’s fluorescence-based quantitative measurement with Caliper’s market-leading multispectral imaging capabilities, users will be afforded a level of quality, performance and reproducibility that is unparalleled. Caliper has outdone itself with enhancements to its earlier product, while HistoRx has ensured that customer needs for high-volume digital fluorescence analysis are addressed through AQUAServe.”
AQUAServe is a server-based queuing software designed to enable ‘walk-away’ operation for multiple specimens while retaining the full functionality of HistoRx’s flagship AQUAnalysis software. AQUAServe will enable high-volume customers to take full advantage of Vectra’s 200-slide loader. Caliper will distribute the integrated product in the research market; the companies are also exploring collaborations in clinical research and diagnostics. Caliper and Vectra are trademarks of Caliper Life Sciences.
